LONDON (ShareCast) - (Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.
The final stage of ValiRx's trials on VAL201, which involves patients with hormone-sensitive and hormone-resistant prostate cancer, comes almost a year after the outfit received approval from the Medicines and Healthcare Products Regulatory Agency to escalate dosing.

ValiRx said it had used the intervening period to gear up VAL201's compound supply chain in order to meet increased demand for the drug after gaining approval for higher dosages.

The AIM-listed firm revealed that current participants had already received the escalated dose and had already demonstrated "consistent safety and tolerability".

Chief executive Dr Satu Vainikka, said: "I am delighted that this trial is ongoing and reaching the final stages and I look forward to the trial further impacting positively on the lives of current and future patients".

As of 0830 BST, ValiRx shares had shot up 8.17% to 1.92p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE